[A case of Paclitaxel-induced peripheral neuropathy successfully treated with duloxetine].

Abstract

Here, we report about a 60-year-old woman with metastatic breast cancer who was successfully treated for paclitaxelinduced peripheral neuropathy with duloxetine. She was administered trastuzumab plus paclitaxel(PTX)combination therapy that was ultimately discontinued because of grade 3 peripheral neuropathy detected on day 15, according to the CTCAE (v4.0). She was administered duloxetine on day 90 after the end of the previous therapy because of the peripheral neuropathy. Thereafter, the peripheral neuropathy decreased to grade 1, which enabled PTX administration on her request. Further trials are required to confirm the efficacy of duloxetine.

• Authors: Satoshi Nagashima, Takayoshi Kiba, Yoshikazu Ogawa, Takuya Mura, Sayoko Kajiume, Yuuko Okada, Nao Morii, Hirotoshi Takahashi, Yasunori Ichiba, Hiroyasu Yamashiro
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 42 Issue 5 Pg. 617-9 (May 2015) ISSN: 0385-0684 [Print] Japan
• PMID: 25981658 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Thiophenes
• Duloxetine Hydrochloride
• Trastuzumab
• Paclitaxel

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Duloxetine Hydrochloride
• Female
• Humans
• Middle Aged
• Paclitaxel (administration & dosage, adverse effects)
• Peripheral Nervous System Diseases (chemically induced, drug therapy)
• Thiophenes (therapeutic use)
• Trastuzumab